A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam,Philip N. Newsome,Shiv Kumar Sarin,Quentin M. Anstee,Giovanni Targher,Manuel Romero-Gómez,Shira Zelber-Sagi,Vincent Wai-Sun Wong,Jean-François Dufour,Jörn M. Schattenberg,Takumi Kawaguchi,Marco Arrese,Luca Valenti,Gamal Shiha,Claudio Tiribelli,Hannele Yki-Järvinen,Jian-Gao Fan,Henning Grønbæk,Yusuf Yilmaz,Helena Cortez-Pinto,Claudia P. Oliveira,Pierre Bedossa,Leon A. Adams,Ming-Hua Zheng,Yasser Fouad,Wah-Kheong Chan,Nahum Méndez-Sánchez,Sang Hoon Ahn,Laurent Castera,Elisabetta Bugianesi,Vlad Ratziu,Jacob George +31 more
TLDR
A panel of international experts from 22 countries propose a new definition of metabolic-dysfunction-associated fatty liver disease that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases.About:
This article is published in Journal of Hepatology.The article was published on 2020-07-01 and is currently open access. It has received 1705 citations till now. The article focuses on the topics: Steatohepatitis & Fatty liver.read more
Citations
More filters
Journal ArticleDOI
Non-alcoholic fatty liver disease
TL;DR: In this paper, a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma, and the leading causes of death in people with NAFLD are cardiovascular disease and extrahepatic malignancy.
Journal ArticleDOI
The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam,Shiv Kumar Sarin,Vincent Wai-Sun Wong,Jian-Gao Fan,Takumi Kawaguchi,Sang Hoon Ahn,Ming-Hua Zheng,Gamal Shiha,Yusuf Yilmaz,Rino Alvani Gani,Shahinul Alam,Yock Young Dan,Jia-Horng Kao,Saeed Hamid,Ian Homer Y. Cua,Wah-Kheong Chan,Diana A. Payawal,Soek Siam Tan,Tawesak Tanwandee,Leon A. Adams,Manoj Kumar,Masao Omata,Jacob George +22 more
TL;DR: The clinical practice guidelines of the Asian Pacific Association for the Study of the Liver on MAFLD are presented to improve patient care and awareness of the disease and assist stakeholders in the decision-making process by providing evidence-based data.
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
Eduardo Vilar-Gomez,Eduardo Vilar-Gomez,Luis Calzadilla-Bertot,Vincent Wai-Sun Wong,Marlen Castellanos,Rocio Aller-de la Fuente,Mayada Metwally,Mohammed Eslam,Licet Gonzalez-Fabian,María Alvarez-Quiñones Sanz,Antonio Felix Conde-Martin,Bastiaan De Boer,Duncan McLeod,Anthony W.H. Chan,Naga Chalasani,Jacob George,Leon A. Adams,Manuel Romero-Gómez +17 more
TL;DR: In this paper, the authors describe long-term outcomes and evaluate the effects of clinical and histologic parameters on disease progression in patients with advanced nonalcoholic fatty liver disease (NAFLD) with bridging fibrosis.
Journal ArticleDOI
Comparison of MAFLD and NAFLD diagnostic criteria in real world.
Su Lin,Jiaofeng Huang,Mingfang Wang,Rajesh Kumar,Yuxiu Liu,Shiying Liu,Yinlian Wu,Xiaozhong Wang,Yueyong Zhu +8 more
TL;DR: This work aimed to compare the characteristics of MAFLD and non‐alcoholic fatty liver disease (NAFLD), a novel concept proposed in 2020 which has not been tested and validated in real world.
Journal ArticleDOI
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease.
Kenneth I. Zheng,Feng Gao,Xiao Bo Wang,Qing-Feng Sun,Ke Hua Pan,Ting Yao Wang,Hong Lei Ma,Yong-Ping Chen,Wen Yue Liu,Jacob George,Ming-Hua Zheng +10 more
TL;DR: The data demonstrate that the risk of obesity to COVID-19 severity is greater in those with, than those without MAFLD, and the presence of obesity inMAFLD patients was associated with a ~ 6-fold increased risk of severe COVID -19 illness.
References
More filters
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Journal ArticleDOI
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
Aram V. Chobanian,George L. Bakris,Henry R. Black,William C. Cushman,Lee A. Green,Joseph L. Izzo,Daniel W. Jones,Barry J. Materson,Suzanne Oparil,Jackson T. Wright,Edward J. Roccella +10 more
TL;DR: The most effective therapy prescribed by the most careful clinician will control hypertension only if patients are motivated, and empathy builds trust and is a potent motivator.
Journal ArticleDOI
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
K. G. M. M. Alberti,Robert H. Eckel,Scott M. Grundy,Paul Zimmet,James I. Cleeman,Karen A. Donato,Jean Charles Fruchart,W. Philip T. James,Catherine M. Loria,Sidney C. Smith +9 more
TL;DR: It was agreed that there should not be an obligatory component, but that waist measurement would continue to be a useful preliminary screening tool, and a single set of cut points would be used for all components except waist circumference, for which further work is required.
Journal ArticleDOI
Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Scott M. Grundy,James I. Cleeman,Stephen R. Daniels,Karen A. Donato,Robert H. Eckel,Barry A. Franklin,David Gordon,Ronald M. Krauss,Peter J. Savage,Sidney C. Smith,John A. Spertus,Fernando Costa +11 more
TL;DR: This statement from the American Heart Association and the National Heart, Lung, and Blood Institute is intended to provide up-to-date guidance for professionals on the diagnosis and management of the metabolic syndrome in adults.
Journal ArticleDOI
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani,Zobair M. Younossi,Joel E. Lavine,Michael Charlton,Kenneth Cusi,Mary E. Rinella,Stephen A. Harrison,Elizabeth M. Brunt,Arun J. Sanyal +8 more
TL;DR: This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care.